Log In
Print
BCIQ
Print
Print this Print this
 

CMB305, ID-CMB305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionCombination of LV305, a lentiviral vector engineered to deliver antigen-carrying nucleic acids to dendritic cells in vivo, and G305, an immunotherapy comprising recombinant cancer/testis antigen 1B (CTAG1B; NY-ESO-1) antigen and GLA-SE adjuvant
Molecular Target
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat locally advanced, relapsed or metastatic solid tumors expressing cancer/testis antigen 1B (CTAG1B; NY-ESO-1)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today